Integra Lifesciences Holdngs (IART) - Friday, Oct 27, 2023
SUMMARY
Key points (machine generated)
- Integra enjoys a high level of trust in the quality and reliability of its products, particularly in the neurosurgical equipment and wound healing grafts segments.
- The acquisition of Codman in 2017 resulted in a significant expansion of Integra's neurosurgery sub-segment.
- Surgeons prefer Integra's brands due to their superior performance and the trust they have in the company's products. The tissue segment uses a variety of raw materials, including animal sources and synthetic materials.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x